LTR's new drug, Spontan, is a “first-in-class” rapid onset, on-demand therapeutic nasal spray for the treatment of ED. The company is nearing commercialization and just completed a successful capital raise that will propel the drug into Australian and US markets in the near future.
Here is my write-up on LTR Pharma simonschase.co... This is not investment advice. Do not rely on the contents of this video. Do your own due diligence.
Негізгі бет Lee Rodne, CEO of LTR Pharma, Discusses His Company's New Nasal Spray Formulation for ED
Пікірлер: 4